BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » cord blood » Page 6

StemCyte Receives Phase II IND Clearance for HLA-Matched Cord Blood Mononuclear Stem Cells (MC001)

January 14, 2019 By Cade Hildreth (CEO) Leave a Comment

Stemcyte

StemCyte Receives Phase II Investigational New Drug (IND) Clearance from the U.S. Food and Drug Administration (FDA)

BALDWIN PARK, Calif., Jan. 3, 2019 — StemCyte is pleased to announce that the U.S. Food and Drug Administration (FDA), on December 14, 2018, approved its Phase II Investigational New Drug (IND) application for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury. [Read more…]

Filed Under: Cord Blood, Press Releases Tagged With: cord blood, Stemcyte

Cesca Therapeutics Receives 510(k) Clearance to Market Its AXP® II AutoXpress® Platform for Clinical Cord Blood Banking

December 4, 2018 By Cade Hildreth (CEO) 1 Comment

RANCHO CORDOVA, Calif., Nov. 19, 2018— Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that its device subsidiary, ThermoGenesis® Corp., has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its proprietary AXP® II AutoXpress® Platform (AXP II) for clinical blood banking.

The AXP II, in combination with the Company’s companion, single-use, cell separation set provides automated, rapid and reliable harvest of stem and progenitor cells from collected units of umbilical cord blood in a “functionally-closed” sterile system. [Read more…]

Filed Under: Cord Blood, Press Releases Tagged With: Cesca Therapeutics, cord blood

Cord Blood Banking Market Consolidation

October 18, 2018 By Cade Hildreth (CEO) 1 Comment

Feature | Cord Blood Banking Market Consolidation

After a rapid growth period through the mid-2000s, the global cord blood banking market reached saturation and stabilized through approximately 2012. Since that time, the market has been aggressively consolidating.

In this article:

  1. Cord Blood Industry Consolidation in the U.S.
  2. Cord Blood Industry Consolidation in Europe
  3. Cord Blood Industry Consolidation in Asia
  4. Cord Blood Industry Consolidation in Latin America
  5. Cord Blood Industry Consolidation in India
  6. Trend of Umbilical Cord Blood Industry Consolidation

[Read more…]

Filed Under: Cord Blood Tagged With: cord blood, cord tissue, perinatal

CHAMP Private Equity Acquires Cell Care, Australia’s Largest Cord Blood Bank

October 11, 2018 By Cade Hildreth (CEO) Leave a Comment

CHAMP Private Equity Cell Care

CHAMP Private Equity is acquiring Cell Care, the largest cord blood bank within Australia, according to news released October 10, 2018, by the Australian Financial Review (AFR).  According to AFR, “It is understood CHAMP will take a controlling stake in the business, while some of the vending shareholders will retain a minority shareholding.”

The transaction has important implications for the global stem cell banking marketplace, because the AFR estimates the deal to have a price tag of more than $100 million.

With this price tag, Cell Care will be well capitalized to continue its research into therapeutic applications of cord blood and tissue stem cells and may be positioned to expand into new markets beyond Australia and Canada.
[Read more…]

Filed Under: Cord Blood, Stem Cell News Tagged With: acquisition, cord blood

Cryo-Cell Acquires CORD:USE for $14 Million, Enters Public Cord Blood Sector

October 1, 2018 By Cade Hildreth (CEO) Leave a Comment

cryo-cell | Cryo-Cell Acquires CORD:USE for $14 Million, Enters Public Cord Blood Sector

On June 4, 2018, Cryo-Cell International announced it will be acquiring the hybrid public-private cord blood bank CORD:USE for $14 million. The acquisition’s purposes are to strengthen its cord blood banking services by entering the public cord blood sector and to solidify its role as an industry leader. Learn about the combined commercial entity of Cryo-Cell CORD:USE below.

Cryo-Cell CORD:USE | The Acquisition of CORD:USE

In this article:

  1. Terms of the Cryo-Cell International and CORD:USE Deal
  2. A Short Background On Cryo-Cell
  3. About CORD:USE
  4. U.S. Cord Blood Market Leaders
  5. GI Partners’s Acquisition of CBR and CCB

[Read more…]

Filed Under: Cord Blood, Stem Cell News Tagged With: cord blood, Cryo-Cell

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 32
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    تم التقييم 0 من 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    تم التقييم 0 من 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    تم التقييم 0 من 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.